Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors:
SEC Accession No. 0000902664-25-000855
Filing Date
2025-02-12
Accepted
2025-02-12 09:30:18
Documents
2

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G  
1 primary_doc.xml SCHEDULE 13G 10830
2 JOINT FILING AGREEMENT p25-0262exhibit99.htm EX-99 3357
  Complete submission text file 0000902664-25-000855.txt   15913
Mailing Address 200 CLARENDON STREET, 52ND FLOOR BOSTON MA 02116
Business Address 200 CLARENDON STREET, 52ND FLOOR BOSTON MA 02116 617-867-2800
Adage Capital Management, L.P. (Filed by) CIK: 0001535978 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G

Mailing Address 10955 VISTA SORRENTO PARKWAY SUITE 200 SAN DIEGO CA 92130
Business Address 10955 VISTA SORRENTO PARKWAY SUITE 200 SAN DIEGO CA 92130 (858) 751-4493
Janux Therapeutics, Inc. (Subject) CIK: 0001817713 (see all company filings)

EIN.: 822289112 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G | Act: 34 | File No.: 005-92596 | Film No.: 25612557
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)